systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»systhiper-705Research ArticleСТАТЬИARTICLESВлияние числа одновременно встречающихся компонентов метаболического синдрома на тяжесть артериальной гипертонии, распространенность и выраженность поражения органов-мишеней у данных больныхЖернаковаЮ. В.noemail@neicon.ruЧазоваИ. Е.noemail@neicon.ruИнститут клинической кардиологии им. А.Л.Мясникова, ФГУ Российский кардиологический научно-производственный комплекс Минздравсоцразвития РФRussian Federation201109022023834751Copyright © Жернакова Ю.В., Чазова И.Е., 20232023Жернакова Ю.В., Чазова И.Е.Жернакова Ю.В., Чазова И.Е.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/705ReferencesFord ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005; 28: 1769-78.Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005; 28: 1769-78.Isomaa B, Lahti K, Almengren P et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-9.Isomaa B, Lahti K, Almengren P et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-9.Eschwege E. The dysmetabolic syndrome, insulin resistance and increased cardiovascular morbidity and mortality in type 2 diabetes: etiological factors in the development of CV complications. Diabetes Metab 2003; 29: 19-27.Eschwege E. The dysmetabolic syndrome, insulin resistance and increased cardiovascular morbidity and mortality in type 2 diabetes: etiological factors in the development of CV complications. Diabetes Metab 2003; 29: 19-27.Golden SH, Folsom AR, Coresh J et al. Risk factor groupings related to insulin resistance and their synergistic effects on subclinical atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) study. Diabetes 2002; 51: 3069-76.Golden SH, Folsom AR, Coresh J et al. Risk factor groupings related to insulin resistance and their synergistic effects on subclinical atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) study. Diabetes 2002; 51: 3069-76.Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003; 289: 2560-72.Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003; 289: 2560-72.European Society of Hypertension-European Society of Cardiology Guidelines Committee. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-53.European Society of Hypertension-European Society of Cardiology Guidelines Committee. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-53.Schillaci G, Pirro M, Vaudo G et al. Prognostic value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol 2004; 19: 1817-22.Schillaci G, Pirro M, Vaudo G et al. Prognostic value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol 2004; 19: 1817-22.McNeill AM, Rosamond WD, Girman CJ et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 2005; 28: 385-90.McNeill AM, Rosamond WD, Girman CJ et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 2005; 28: 385-90.Ford ES. The metabolic syndrome and mortality from cardiovascular disease and all-causes: Findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 2004; 173: 309-14.Ford ES. The metabolic syndrome and mortality from cardiovascular disease and all-causes: Findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 2004; 173: 309-14.Иевлева Г.И., Тесля Е.Ф., Биктимирова Д.М. и соавт. Показатели суточного артериального давления у больных с метаболическим синдромом. Клиническая медицина 2009; 6: 15-9.Иевлева Г.И., Тесля Е.Ф., Биктимирова Д.М. и соавт. Показатели суточного артериального давления у больных с метаболическим синдромом. Клиническая медицина 2009; 6: 15-9.Eguchi K. Ambulatory blood pressure monitoring in diabetes and obesity - a review. Int J Hypertens 2011; doi:10.4061/2011/954757.Eguchi K. Ambulatory blood pressure monitoring in diabetes and obesity - a review. Int J Hypertens 2011; doi:10.4061/2011/954757.Soylu A, Güleç H, Alihanoğlu Yİ et al. The effect of nondipper blood pressure pattern on target organ damage in patients with metabolic syndrome. Türk Kardiyol Dern Arş 2009; 37: 454-60.Soylu A, Güleç H, Alihanoğlu Yİ et al. The effect of nondipper blood pressure pattern on target organ damage in patients with metabolic syndrome. Türk Kardiyol Dern Arş 2009; 37: 454-60.Cuspidi C, Meani S,Valerio C et al. Metabolic syndrome score and ambulatory blood pressure in untreated essential hypertension. Blood Pressure Monitoring 2005; 10 (4): 175-80.Cuspidi C, Meani S,Valerio C et al. Metabolic syndrome score and ambulatory blood pressure in untreated essential hypertension. Blood Pressure Monitoring 2005; 10 (4): 175-80.Mulè G, Nardi E, Cottone S et al. Influence of metabolic syndrome on hypertension-related target organ damage. J Intern Med 2005; 257 (6): 503-13.Mulè G, Nardi E, Cottone S et al. Influence of metabolic syndrome on hypertension-related target organ damage. J Intern Med 2005; 257 (6): 503-13.Kawamoto R, Tomita H, Oka Y et al. Metabolic syndrome amplifies the LDL-cholesterol associated increases in carotid atherosclerosis. Intern Med 2005; 44: 1232-38.Kawamoto R, Tomita H, Oka Y et al. Metabolic syndrome amplifies the LDL-cholesterol associated increases in carotid atherosclerosis. Intern Med 2005; 44: 1232-38.Schillaci G, Pirro M, Vaudo G et al. Metabolic syndrome is associated with aortic stiffness in untreated essential hypertension. Hypertension 2005; 45: 1978-82.Schillaci G, Pirro M, Vaudo G et al. Metabolic syndrome is associated with aortic stiffness in untreated essential hypertension. Hypertension 2005; 45: 1978-82.Cuspidi C, Meani S, Fusi V et al. Prevalence and correlates of left atrial enlargement in essential hypertension: role of ventricular geometry and the metabolic syndrome: the Evaluation of Target Organ Damage in Hypertension study. J Hypertens 2005; 23: 875-82.Cuspidi C, Meani S, Fusi V et al. Prevalence and correlates of left atrial enlargement in essential hypertension: role of ventricular geometry and the metabolic syndrome: the Evaluation of Target Organ Damage in Hypertension study. J Hypertens 2005; 23: 875-82.Cuspidi C, Meani S, Valerio C et al. Ambulatory blood pressure, target organ damage and left atrial size in never-treated essential hypertensive individuals. J Hypertens 2005; 23: 1589-95.Cuspidi C, Meani S, Valerio C et al. Ambulatory blood pressure, target organ damage and left atrial size in never-treated essential hypertensive individuals. J Hypertens 2005; 23: 1589-95.Sega R, Trocino G, Lanzarotti A et al. Alterations of cardiac structure in patients with isolated office, ambulatory, or home hypertension: data from the general population (Pressione Arteriose Monitorate e Loro Associazioni [PAMELA] Study). Circulation 2001; 104: 1385-92.Sega R, Trocino G, Lanzarotti A et al. Alterations of cardiac structure in patients with isolated office, ambulatory, or home hypertension: data from the general population (Pressione Arteriose Monitorate e Loro Associazioni [PAMELA] Study). Circulation 2001; 104: 1385-92.Cuspidi C, Valerio C, Giudici V et al. Metabolic syndrome and multiple organ damage in essential hypertension. Blood Pressure 2008а; 17: 195-203.Cuspidi C, Valerio C, Giudici V et al. Metabolic syndrome and multiple organ damage in essential hypertension. Blood Pressure 2008а; 17: 195-203.Navarro J, Redón J, Cea-Calvo L et al. Metabolic syndrome, organ damage and cardiovascular disease in treated hypertensive patients. The ERICHTA study. Blood Press 2007; 16 (1): 20-7.Navarro J, Redón J, Cea-Calvo L et al. Metabolic syndrome, organ damage and cardiovascular disease in treated hypertensive patients. The ERICHTA study. Blood Press 2007; 16 (1): 20-7.Eguchi K, Schwartz JE, Roman MJ et al. Metabolic syndrome less strongly associated with target organ damage than syndrome components in a healthy, working population. J Clin Hypertens (Greenwich) 2007; 9 (5): 337-44.Eguchi K, Schwartz JE, Roman MJ et al. Metabolic syndrome less strongly associated with target organ damage than syndrome components in a healthy, working population. J Clin Hypertens (Greenwich) 2007; 9 (5): 337-44.Cuspidi C, Meani S, Valerio C et al. Age and target organ damage in essential hypertension: role of the metabolic syndrome. Am J Hypertens 2007; 20 (3): 296-303.Cuspidi C, Meani S, Valerio C et al. Age and target organ damage in essential hypertension: role of the metabolic syndrome. Am J Hypertens 2007; 20 (3): 296-303.Cuspidi C, Sala C, Zanchetti A. Metabolic syndrome and target organ damage: role of blood pressure. Expert Rev Cardiovasc Ther 2008; 6 (5): 731-43.Cuspidi C, Sala C, Zanchetti A. Metabolic syndrome and target organ damage: role of blood pressure. Expert Rev Cardiovasc Ther 2008; 6 (5): 731-43.Tatasciore A, Renda G, Zimarino M et al. Awake systolic blood pressure variability correlates with target-organ damage in hypertensive subjects. Hypertension 2007; 50 (2): 325-2.Tatasciore A, Renda G, Zimarino M et al. Awake systolic blood pressure variability correlates with target-organ damage in hypertensive subjects. Hypertension 2007; 50 (2): 325-2.Шарипова Г.М. Особенности поражения органов-мишеней у больных артериальной гипертонией в зависимости от наличия и отсутствия метаболического синдрома. 2009.Шарипова Г.М. Особенности поражения органов-мишеней у больных артериальной гипертонией в зависимости от наличия и отсутствия метаболического синдрома. 2009.Azeveda A, Bettencourt P, Almeida PB et al. Increasing number of components of the metabolic syndrome and cardiac structural and functional abnormalities - cross-sectional study of the general population. BMS Cardiovascular Disorders 2007; 7: 17.Azeveda A, Bettencourt P, Almeida PB et al. Increasing number of components of the metabolic syndrome and cardiac structural and functional abnormalities - cross-sectional study of the general population. BMS Cardiovascular Disorders 2007; 7: 17.Leoncini G, Ratto E, Viazzi F et al. Metabolic syndrome is associated with early signs of organ damage in non-diabetic, hypertensive patients. J Intern Med 2005; 257: 454-60.Leoncini G, Ratto E, Viazzi F et al. Metabolic syndrome is associated with early signs of organ damage in non-diabetic, hypertensive patients. J Intern Med 2005; 257: 454-60.Kincaid-Smith P. Hypothesis: obesity and the insulin resistance syndrome play a major role in end stage renal failure attributed to hypertension and labeled «hypertensive nephrosclerosis». J Hypertens 2004; 22: 105-55.Kincaid-Smith P. Hypothesis: obesity and the insulin resistance syndrome play a major role in end stage renal failure attributed to hypertension and labeled «hypertensive nephrosclerosis». J Hypertens 2004; 22: 105-55.Mykkanen L, Zaccaro DJ, Wagenknecht LE et al. Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the Insulin Resis-tance Atherosclerosis Study. Diabetes 1998; 47: 793-800.Mykkanen L, Zaccaro DJ, Wagenknecht LE et al. Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the Insulin Resis-tance Atherosclerosis Study. Diabetes 1998; 47: 793-800.Abuaisha B, Kumar S, Malik R, Boulton AJ. Relationship of elevated urinary albumin excretion to components of the metabolic syndrome in non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1998; 39 (2): 93-9.Abuaisha B, Kumar S, Malik R, Boulton AJ. Relationship of elevated urinary albumin excretion to components of the metabolic syndrome in non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1998; 39 (2): 93-9.Cuspidi C, Meani S, Fusi V et al. Metabolic syndrome and target organ damage in untreated essential hypertensives. J Hypertens 2004; 22: 1991-98.Cuspidi C, Meani S, Fusi V et al. Metabolic syndrome and target organ damage in untreated essential hypertensives. J Hypertens 2004; 22: 1991-98.Chen J, Muntner P, Hamm LL et al. The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med 2004; 140: 167-74.Chen J, Muntner P, Hamm LL et al. The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med 2004; 140: 167-74.

The authors declare that there are no conflicts of interest present.